The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Meridian Bioscience Inc

Nasdaq: VIVO
Last

(U.S.) $16.86

Today's change+0.56 +3.44%
Updated December 17 4:00 PM EST. Delayed by at least 15 minutes.
 

Meridian Bioscience Inc

Nasdaq: VIVO
Last

(U.S.) $16.86

Today's change+0.56 +3.44%
Updated December 17 4:00 PM EST. Delayed by at least 15 minutes.

Meridian Bioscience Inc crosses above 20-day moving average

Meridian Bioscience Inc closed up sharply Wednesday, rallying (U.S.)$0.56 or 3.44% to (U.S.)$16.86 and crossing above its 20-day moving average. Over the last five days, shares have gained 2.18%, but are down 36.45% for the last year to date. Shares have underperformed the S&P 500 by 45.53% during the last year.

Key company metrics

  • Open(U.S.) $16.30
  • Previous close(U.S.) $16.30
  • High(U.S.) $16.89
  • Low(U.S.) $16.21
  • Bid / Ask(U.S.) $0.00 / (U.S.) $16.85
  • YTD % change-36.45%
  • Volume267,044
  • Average volume (10-day)232,861
  • Average volume (1-month)328,334
  • Average volume (3-month)267,738
  • 52-week range(U.S.) $15.80 to (U.S.) $27.72
  • Beta1.32
  • Trailing P/E20.42×
  • P/E 1 year forward19.01×
  • Forward PEG1.78×
  • Indicated annual dividend(U.S.) $0.80
  • Dividend yield4.74%
  • Trailing EPS(U.S.) $0.83
Updated December 17 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+18.40%

Based on its net profit margin of 18.40%, Meridian Bioscience Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX2.54%Sector:HealthcareIndustry:Medical Equipment, Supplies & Distribution
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue47475045
Total other revenue--------
Total revenue47475045
Gross profit28293228
Total cost of revenue18181917
Total operating expense35343433
Selling / general / administrative13131314
Research & development3333
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0------
Other operating expenses, total--------
Operating income12131612
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax12131611
Income after tax89107
Income tax, total4454
Net income89107
Total adjustments to net income--------
Net income before extra. items89107
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items89107
Inc. avail. to common incl. extra. items89107
Diluted net income89107
Dilution adjustment--0----
Diluted weighted average shares42424242
Diluted EPS excluding extraordinary itemsvalue per share0.200.210.240.18
Dividends per sharevalue per share0.200.200.200.19
Diluted normalized EPSvalue per share0.200.210.240.18